Zepbound

1,227.60$

Zepbound is an injectable prescription medicine used for chronic weight management in adults. It is indicated for those with a body mass index (BMI) of at least 30 kg/m^2 or at least 27 kg/m^2 with at least one weight-related comorbid condition, and it should be administered alongside a reduced-calorie diet and increased physical activity​. Zepbound, known by its generic name tirzepatide, targets both the GLP-1 and GIP hormones and has shown up to 21% weight loss in clinical trials. Common side effects reported include nausea, diarrhea, and vomiting​.

In the competitive landscape of weight loss medications, Zepbound will primarily compete with Novo Nordisk’s Wegovy, which is a similar weight loss medication​. The U.S. Food and Drug Administration (FDA) has also approved tirzepatide for treating obesity, and it is sold under the brand name Mounjaro when used as a diabetes medication, manufactured by Eli Lilly and Co​.

Regarding cost, Zepbound is priced 20% less than its main competitor Wegovy for those with insurance coverage, though the cost remains high at over £500 for a month’s supply. Eli Lilly has announced a discount program for those whose insurance does not cover anti-obesity treatments, offering a 50% discount to these patients​.

SKU: S/N Category:
Translate »
error: Content is protected !!